The core of  NIRAMAI solution is Thermalytix, a computer aided diagnostic engine that is powered by Artificial Intelligence. The solution uses a high resolution thermal sensing device and a cloud hosted analytics solution for analysing the thermal images. Our SaaS solution uses big data analytics, artificial intelligence and machine learning for reliable, early and accurate breast cancer screening. The innovative methods used in our solution have led to multiple US patents. Our novel algorithms have also been peer-reviewed in international scientific conferences.

Our cancer screening tool, SMILE, has been tested on more than 4000 women in 12 hospitals/diagnostic center as well as screening camps. 3 clinical trials, comparing Thermalytix with current standard of care, have been published in peer  reviewed conference/journals. The results from these clinical trials indicate very high accuracy of Thermalytix that is comparable and sometimes better that Mammography.

Below is a summary of the results from trials done so far:

  • Over 90% sensitivity in all trials
  • 27% higher accuracy than Mammography (most of the additional cancers detected were in dense breasts)
  • 70%  higher positive predictive value than Visual interpretation of Thermography (results from traditional thermography are very subjective and error prone)
  • Thermalytix is effective in 32% more patients walking into a hospital with pain or discomfort in their breasts (as it works for younger women/dense breast women)
  • Was able to detect cancer lesions as small as 4 mm with no palpable lumps.
The novel algorithms in Thermalytix have resulted in 6 Granted  patents so far:  US Patent 9622698, US Patent 10055542, US Patent 9486146, US Patent 10068330, US Patent 9898817, US Patent 9865052